Literatur
- 01
Agnelli G .
Gallus A .
Goldhaber SZ .
et al .
Treatment of proximal deep-vein thrombosis with the oral, direct Factor Xa inhibitor,
rivaroxaban (BAY 59-7939): the ODIXa-CVT (Oral Direct Factor Xa Inhibitior BAY 59-7939
in Patients With Acute Symptomatic Deep-Vein Thrombosis) study.
Circulation.
2007;
116: (2)
180-187
- 02
Büller HR .
Once-daily treatment with an oral, direct Factor Xa inhibitor - rivaroxaban (Bay 59-7939)
in patients with acute, symptomatic deep vein thrombosis. The EINSTEIN-DVT dose-finding
study.
Eur Heart J.
2006;
27: (Abstract Suppl)
761
- 03 Lassen MR . Turpie AGG . Rosencher N . et al . Rivaroxaban - an oral, direct Factor
Xa inhibitor - for the prevention of venous thromboembolism in total knee replacement
surgery: results of the RECORD3 study. Oral presentation at the XXIst Congress of
the International Society on Thrombosis and Haemostatis, Geneva, Switzerland, 6-12
Juli 2007.
1 REgulation of Coagulation in major Orthopaedic surgery reducing the Risk of DVT and
pulmonary embolism
2 Oral Direct Factor Xa Inhibitor BAY 59-7939 in patients with acute symptomatic Deep-Vein
Thrombosis
3 Oral direct factor Xa inhibitor rivaroxaban in patients with acute symptomatic deep-vein
thrombosis without symptomatic pulmonary embolism
